SCHEMBL25501032

SCHEMBL25501032

CN1CCOc2ccc(-c3csc(NC(=O)CNC(=O)c4ccc5c(c4)[C@](C)(CO)CC5)n3)cc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 11/20 0.44
▸ MAPT P10636 9/20 0.44
▸ ALDH1A1 P00352 8/20 0.44
▸ RAB9A P51151 7/20 0.44
▸ NPC1 O15118 6/20 0.44
▸ LMNA P02545 6/20 0.44
▸ NFKB1 P19838 1/20 0.44
▸ NFKB2 Q00653 1/20 0.44
▸ RELA Q04206 1/20 0.44
▸ KMT2A Q03164 9/20 0.43
▸ MEN1 O00255 8/20 0.43
▸ GAA P10253 1/20 0.43
▸ CLK1 P49759 2/20 0.43
▸ KDM4E B2RXH2 3/20 0.41
▸ TSHR P16473 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ CYP3A4 P08684 1/20 0.39
▸ USP2 O75604 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ POLB P06746 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25501046 1.00 SMN1; SMN2 (0.44) SMN1; SMN2MAPTALDH1A1RAB9ANPC1
SCHEMBL25501179 0.85 KDM4E (0.41) SMN1; SMN2MAPTALDH1A1RAB9ALMNA
SCHEMBL25502295 0.85 KDM4E (0.41) SMN1; SMN2MAPTALDH1A1RAB9ALMNA
SCHEMBL25501088 0.84 ROCK2 (0.40) SMN1; SMN2MAPTALDH1A1RAB9ANPC1
SCHEMBL25502298 0.83 MEN1 (0.38) SMN1; SMN2MAPTALDH1A1RAB9ANPC1
SCHEMBL25501160 0.83 MEN1 (0.38) SMN1; SMN2MAPTALDH1A1RAB9ANPC1
SCHEMBL25501064 0.81 MAPT (0.37) SMN1; SMN2MAPTALDH1A1RAB9ANPC1
SCHEMBL25502276 0.81 MAPT (0.37) SMN1; SMN2MAPTALDH1A1RAB9ANPC1
SCHEMBL22306344 0.81 RAB9A (0.52) SMN1; SMN2MAPTALDH1A1RAB9ANPC1
SCHEMBL25501203 0.81 KMT2A (0.38) SMN1; SMN2MAPTALDH1A1RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230149414-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB SMN1; SMN2 40/4885MAPT 2074/4885ALDH1A1 2571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback